M80 buys Strapharm

The GP acquired a majority stake of over 75% in Strapharm, which is valued in the €25-50m bracket, Unquote has learned.

M80 will support the business in its growth plans in France and abroad via a buy-and-build strategy. The transaction was supported by senior debt, Unquote understands.

M80, founded in 2018, is investing via M80 Capital I, which held a first close on €100m in Q4 last year. The fund set a €200m target and plans to invest in Benelux and France in companies with a €25-300m turnover within the sectors of consumer, healthcare, business and industrial services. The GP was planning to provide tickets in the €10-40m range.

M80 previously invested in Eurodommages, Gandi.net and Theuma.

Company
Founded in 1987 and based in Saint-Hilaire-de-Loulay, Strapharm is a contract development and manufacturing company for food supplements, servicing food supplement brands and retailers in France and internationally. Its products support immunity and help sports performance among other things. They also have a range for pets.

The company operates an R&D and production site in Nantes and employs about 30 people. Strapharm generated a turnover of just under €5.3m in 2018, according to the company's website.

People
M80 – Arnaud de Yrigoyen (CEO); Laurent Catry (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• France
• Consumer
• France